Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 18/20 | 0.64 |
| ▸ | NR1H3 | Q13133 | 10/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3279728 | 0.86 | NR1H2 (0.63) | NR1H2NR1H3 | |
| SCHEMBL3278032 | 0.82 | NR1H2 (0.58) | NR1H2NR1H3NPC1CYP2D6CYP2C19 | |
| SCHEMBL3277956 | 0.79 | ALDH1A1 (0.58) | NR1H2NR1H3NPC1ALDH1A1 | |
| SCHEMBL3280350 | 0.79 | NR1H2 (0.64) | NR1H2NR1H3 | |
| SCHEMBL3279745 | 0.78 | NR1H2 (1.00) | NR1H2NR1H3 | |
| SCHEMBL3279324 | 0.77 | NR1H2 (1.00) | NR1H2NR1H3 | |
| SCHEMBL3282748 | 0.77 | NR1H2 (0.61) | NR1H2NR1H3MAPT | |
| SCHEMBL1125267 | 0.76 | NR1H2 (0.66) | NR1H2NR1H3 | |
| SCHEMBL3279021 | 0.76 | NR1H2 (0.76) | NR1H2NR1H3 | |
| SCHEMBL3278540 | 0.76 | NR1H2 (0.52) | NR1H2NR1H3MAPTALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700595-B2 | such as 3-benzyl-4-phenyl-8-(trifluoromethyl)cinnoline; modulators of Liver X receptors (LXRs) | WYETH LLC (US) | 2010-04-20 | — | — | US | claimed |
| EP-1853566-A1 | CINNOLINE COMPOUNDS AND THEIR USE AS LIVER X RECEPTOR MODULATORS | Wyeth (US) | 2007-11-14 | — | — | EP | claimed |
| WO-2006094034-A1 | CINNOLINE COMPOUNDS AND THEIR USE AS LIVER X RECEPTOR MODILATORS | WYETH (US) | 2006-09-08 | — | — | WO | claimed |
| US-7700595-B2 | such as 3-benzyl-4-phenyl-8-(trifluoromethyl)cinnoline; modulators of Liver X receptors (LXRs) | WYETH LLC (US) | 2010-04-20 | — | — | US | disclosed |
| EP-1853566-A1 | CINNOLINE COMPOUNDS AND THEIR USE AS LIVER X RECEPTOR MODULATORS | Wyeth (US) | 2007-11-14 | — | — | EP | disclosed |
| US-20060252757-A1 | Cinnoline compounds | WYETH | 2006-11-09 | — | — | US | disclosed |
| WO-2006094034-A1 | CINNOLINE COMPOUNDS AND THEIR USE AS LIVER X RECEPTOR MODILATORS | WYETH (US) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252757-A1 | Cinnoline compounds | NR1H3, NR1H2, CNR1 | NR1H2 2/4885NR1H3 1/4885MAPT 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.